Abstract:Objective To summarize and update information regarding drug-drug interactions (DDIs) between antiretrovirals (ARVs) and hormonal contraceptives (HCs). Design Systematic review Methods We searched seven databases for peer-reviewed publications from January 1, 2015, through December 31, 2023, including studies of women using ARVs and HCs concurrently with outcomes including therapeutic effectiveness or toxicity, pharmacokinetics (PK), or pharmacodynamics. We summarized findings and used checklists to assess evidence quality. Results We included 49 articles, with clinical, ARV or HC PK outcomes reported by 39, 25, and 30 articles, respectively, with some articles reporting outcomes in two or more categories. Fifteen of 18 articles assessing DDIs between efavirenz and progestin implants, emergency contraception, or combined hormonal intravaginal rings found higher pregnancy rates, luteal progesterone levels suggesting ovulation, or reduced progestin PK values. Five studies documented that CYP2B6 single nucleotide polymorphisms exacerbated this DDI. One cohort detected doubled bone density loss with concomitant depot medroxyprogesterone acetate (DMPA) and tenofovir disoproxil fumarate (TDF)-containing ART use versus TDF alone. No other studies described DDIs impacting clinical outcomes. Few adverse events were attributed to ARV-HC use with none exceeding Grade 2. Evidence quality was generally moderate, with dis-similar treatment and control groups, identifying and controlling for confounding, and minimizing attrition bias in the study design being the most frequent limitations. Conclusion Most ARVs and HCs may be used safely and effectively together. TDF-DMPA DDIs warrant longer-term study on bone health and consideration of alternate combinations. For efavirenz-based ART, client counselling on relative risks, including both potential increase in pregnancy rate with concomitant efavirenz and implant use and lower pregnancy rates compared to other HCs even with concomitant efavirenz use, should continue to allow users comprehensive method choice.

Antiretroviral Drug Interactions: Overview of Interactions Involving New and Investigational Agents and the Role of Therapeutic Drug Monitoring for Management

A regulatory perspective on the role of drug interactions in antiretroviral drug development

The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy

Drug Interactions in Antiretroviral Therapy and Treatment for Occasional Infections

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Rational Prescription of Drugs Within Similar Therapeutic or Structural Class for Gastrointestinal Disease Treatment： Drug Metabolism and Its Related Interactions

Drug–drug interactions in HIV-infected patients receiving chemotherapy

Pharmacokinetic Interactions of HIV Protease Inhibitors

Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

Drug–drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems

Analysis of drug-drug interactions in patients with HIV and metabolic syndrome

Progress of therapeutic drug monitoring in high active antiretroviral therapy

Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study

Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects

Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions

Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017

HIV–TB Coinfection: Current Therapeutic Approaches and Drug Interactions

Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics

Management of anticoagulation in patients with human immunodeficiency virus/acquired immunodeficiency virus

Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians

Drug-Drug Interactions between Antiretrovirals and Hormonal Contraception: An Updated Systematic Review